All articles tagged with #car t cell therapy
CAR T cell therapy has transformed blood cancer treatment, achieving high survival rates, but faces hurdles in cost, side effects, and expanding to solid tumors. Recent FDA approvals for myeloma and myeloproliferative disorders highlight broader immunotherapy advances, while experts debate next-generation designs and accessibility.
A three-year-old boy with chemotherapy-resistant, metastatic hepatoblastoma achieved complete disease regression after receiving two doses of experimental GPC3-CAR T-cell therapy. Published in The New England Journal of Medicine, the case demonstrates that this immunotherapy can effectively treat solid tumors in an outpatient setting without systemic toxicity. The boy, who had previously undergone surgery and chemotherapy with rapid recurrence, remains disease-free after 12 months. This milestone suggests potential for treating other GPC3-positive solid tumors, though further trials are needed to confirm safety and efficacy across broader populations.
Numan Unees, a 40-year-old from Rotherham, becomes the first Sheffield participant in a global CAR T cell trial for progressive MS; researchers hope the cancer-derived immunotherapy can reset the immune system and stop disability, potentially changing the treatment landscape if safety and efficacy are proven.
A first-in-humans trial of a multi-target CAR-T-cell therapy for pediatric brain tumors shows it can safely generate anti-tumor responses and durable remissions, targeting WT1, PRAME and Survivin, with plans to advance to Phase 2 toward FDA approval.
Sam Neill, the Jurassic Park actor, has died at 78 after a battle with stage 3 angioimmunoblastic T-cell lymphoma. His ex, Laura Tingle, said the cancer and its treatments left him immunocompromised and exhausted, though he was declared cancer-free in April after a CAR T-cell therapy trial. The family announced his death as sudden and unexpected, noting he remained cancer-free and thanking his hospital staff; tributes from co-stars followed as Neill’s dedication to acting and resilience were highlighted.
A UK trial at University College London Hospital using CAR T-cell therapy to treat lupus nephritis showed remission in five of nine patients within three months, with remissions lasting through an 11-month follow-up, including a patient who fulfilled a skiing dream—an advance that researchers say could herald a lupus cure if confirmed in larger studies.
Cold Spring Harbor Laboratory researchers used anti-uPAR CAR T cells to selectively clear senescent cells in aging intestinal tissue, boosting epithelial regeneration, reducing inflammation, and improving nutrient absorption in both young and old mice. After radiation-induced gut damage, treated mice recovered more fully, with benefits persisting for at least a year. Early data also show regeneration signals in human intestinal and colorectal cells, suggesting potential clinical trials to counter age-related gut decline.
Scientists have successfully engineered cancer-fighting T-cells inside patients' bodies for the first time, potentially making CAR T-cell therapy faster, cheaper, and more accessible for treating multiple myeloma, with promising early results and manageable side effects.
A Hertfordshire mother and biology teacher, Emily Henders, has become the first UK patient to receive a pioneering CAR T cell therapy in a clinical trial aimed at treating multiple sclerosis, a disease that causes immune system attacks on nerves. The experimental treatment, which depletes B cells to reset the immune system, offers hope for slowing or halting disease progression and could be a gamechanger if successful.
A new FDA-approved treatment called Carvykti, a CAR T-cell therapy developed by Legend Biotech in New Jersey, offers a potential 'functional cure' for multiple myeloma, significantly extending remission periods and improving quality of life for patients like Carmen Phaneuf, who has managed to stay in remission for nearly three years after treatment.
A study from the University of Pennsylvania suggests that a ketogenic diet enhances the effectiveness of CAR T cell therapy in treating lymphoma by utilizing beta-hydroxybutyrate (BHB) as a preferred energy source over glucose. This approach led to improved tumor control and survival in mice, with translational studies indicating similar benefits in human samples. A Phase I clinical trial is underway to test BHB supplementation in lymphoma patients, potentially offering a low-toxicity, cost-effective strategy to boost cancer immunotherapy outcomes.
A new CAR T-cell therapy shows promise in treating glioblastoma, a deadly brain cancer, by using the patient's immune system to target cancer cells. In a small trial, one patient experienced significant tumor shrinkage without recurrence, while two others saw initial improvements but later relapsed. Despite mixed results, the therapy offers hope for a cancer with limited treatment options, prompting further research.
A new treatment for lupus, using CAR T-cell therapy, is being hailed as groundbreaking, potentially eliminating the need for lifelong medication. This therapy, which genetically modifies a patient's cells to fight the autoimmune disease, has shown promising results in Germany, with patients achieving remission. In the UK, three patients have received the treatment, including a 32-year-old woman who reported improved energy and reduced symptoms. The therapy, previously used for cancer, could revolutionize lupus treatment and possibly lead to a cure, though it involves risks such as increased infection susceptibility.
A new immunotherapeutic approach using CAR T-cell therapy has shown promising results in treating glioblastoma, a deadly form of brain cancer. In a small clinical trial, one patient experienced a significant reduction in tumor size within days of receiving the treatment, while others saw mixed outcomes. The therapy targets a mutated protein prevalent in glioblastomas, and researchers are optimistic about its potential as a treatment, although long-term effectiveness is still unknown. Further study and clinical trials are needed to determine the therapy's efficacy in treating this incurable disease.
Early clinical trials have shown promise for a new immune cell-based treatment, CAR T-cell therapy, in shrinking tumors in patients with recurrent glioblastoma, a highly aggressive form of brain cancer. The therapy involves genetically modifying patients' immune cells to better recognize and attack tumors. While the treatment was found to be safe and reduced tumor size in all nine patients, the effects were not necessarily long-lasting. More data is needed to evaluate the longer-term effects and broader relevance of these new treatments, but researchers are optimistic about the potential of CAR T-cell therapy to make a difference in solid tumors, especially in the brain.